Accolade, Inc. - common stock (ACCD)
6.9500
0.00 (0.00%)
Accolade Inc is a technology-driven healthcare company that offers personalized health and benefits solutions
The company leverages data analytics and artificial intelligence to provide individuals and employers with tailored guidance in navigating complex healthcare systems. By pairing users with dedicated health assistants, Accolade aims to simplify healthcare decisions, enhance user experience, and improve health outcomes while helping organizations manage costs associated with employee health benefits. Through its innovative platform, the company optimizes access to care, navigates insurance options, and supports overall wellness initiatives.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Accolade, Inc. (NASDAQACCD) to Transcarent for $7.03 per share in cash is fair to Accolade shareholders.
By Halper Sadeh LLC · Via Business Wire · February 25, 2025

NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · February 19, 2025

BALA CYNWYD, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · February 19, 2025
Accolade Inc. (NASDAQ: ACCD) Leading the Way in Tuesday Trading Based on Percentage Gain
Accolade, Inc. (NASDAQACCD) is one of today’s top gainers. The company’s shares have moved -0.61% on the day to $6.52.
Via Investor Brand Network · January 9, 2024

BALA CYNWYD, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · January 13, 2025

NEW YORK, Jan. 11, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · January 11, 2025

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Accolade, Inc. (NasdaqGS: ACCD) to Transcarent. Under the terms of the proposed transaction, shareholders of Accolade will receive $7.03 in cash for each share of Accolade that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
By Kahn Swick & Foti, LLC · Via Business Wire · January 8, 2025

Ademi LLP is investigating Accolade (NASDAQACCD) for possible breaches of fiduciary duty and other violations of law in its transaction with the Transcarent.
By Ademi LLP · Via Business Wire · January 8, 2025

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Accolade, Inc. (NASDAQACCD) to Transcarent for $7.03 per share in cash is fair to Accolade shareholders.
By Halper Sadeh LLC · Via Business Wire · January 8, 2025

Transcarent, the One Place for Health and Care, and Accolade (NASDAQACCD), a leader in health advocacy, expert medical opinions, and primary care, announced that they have entered into a definitive agreement under which Transcarent will acquire Accolade for $7.03 per share in cash, which represents a total equity value of approximately $621M. This strategic combination, which has been unanimously approved by the Boards of Directors of both companies, will enhance Transcarent's mission to make it easy for people to access high-quality, affordable health and care. The combined platform will deliver a more personalized and engaging Member experience.
By Transcarent · Via Business Wire · January 8, 2025

Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment
By Accolade, Inc. · Via GlobeNewswire · January 8, 2025

SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQACCD) today announced financial results for the fiscal second quarter ended August 31, 2024.
By Accolade, Inc. · Via GlobeNewswire · October 8, 2024

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. (“Accolade” or “the Company”) (NASDAQACCD). Investors who purchased Accolade securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ACCD.
By Bronstein, Gewirtz & Grossman, LLC · Via Business Wire · July 15, 2024

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. (“Accolade” or “the Company”) (NASDAQACCD). Investors who purchased Accolade securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ACCD.
By Bronstein, Gewirtz & Grossman, LLC · Via Business Wire · July 9, 2024

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Accolade, Inc. (“Accolade” or “the Company”) (NASDAQACCD) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · June 27, 2024

SEATTLE, April 25, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQACCD) today announced financial results for the fiscal fourth quarter and full year ended February 29, 2024.
By Accolade, Inc. · Via GlobeNewswire · April 25, 2024

SEATTLE, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQACCD) today announced financial results for the fiscal third quarter ended November 30, 2023.
By Accolade, Inc. · Via GlobeNewswire · January 8, 2024

SEATTLE, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQACCD) today announced financial results for the fiscal second quarter ended August 31, 2023.
By Accolade, Inc. · Via GlobeNewswire · October 4, 2023

As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week
Via MarketBeat · July 15, 2023

Accolade Inc. (NASDAQACCD) provides an artificial intelligence (AI)-powered healthcare platform. Learn more about Accolade Inc. stock.
Via MarketBeat · July 11, 2023

SEATTLE, June 29, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQACCD) today announced financial results for the fiscal first quarter ended May 31, 2023.
By Accolade, Inc. · Via GlobeNewswire · June 29, 2023

SEATTLE, April 27, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQACCD) today announced financial results for the fiscal fourth quarter and full year ended February 28, 2023.
By Accolade, Inc. · Via GlobeNewswire · April 27, 2023
Accolade Inc. (NASDAQ: ACCD) Records 52-Week High Thursday Morning
Shares of Accolade, Inc. (NASDAQACCD) traded at a new 52-week high today and are currently trading at $16.56. So far today, approximately 272k shares have been exchanged, as compared to an average 30-day volume of 462.6k shares.
Via Investor Brand Network · April 27, 2023
Accolade Inc. (NASDAQ: ACCD) Records 52-Week High Wednesday Morning
Shares of Accolade, Inc. (NASDAQACCD) traded at a new 52-week high today and are currently trading at $14.72. So far today, approximately 192.23k shares have been exchanged, as compared to an average 30-day volume of 501.17k shares.
Via Investor Brand Network · April 12, 2023

SEATTLE, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQACCD) today announced financial results for the fiscal third quarter ended November 30, 2022.
By Accolade, Inc. · Via GlobeNewswire · January 9, 2023